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Abstract
Integration of retroviral DNA is an obligatory step of retrovirus replication because proviral DNA
is the template for productive infection. Integrase, a retroviral enzyme, catalyses integration. The
process of integration can be divided into two sequential reactions. The first one, named 3'-
processing, corresponds to a specific endonucleolytic reaction which prepares the viral DNA
extremities to be competent for the subsequent covalent insertion, named strand transfer, into the
host cell genome by a trans-esterification reaction. Recently, a novel specific activity of the full
length integrase was reported, in vitro, by our group for two retroviral integrases (HIV-1 and PFV-
1). This activity of internal cleavage occurs at a specific palindromic sequence mimicking the LTR-
LTR junction described into the 2-LTR circles which are peculiar viral DNA forms found during
viral infection. Moreover, recent studies demonstrated the existence of a weak palindromic
consensus found at the integration sites. Taken together, these data underline the propensity of
retroviral integrases for binding symmetrical sequences and give perspectives for targeting specific
sequences used for gene therapy.
Background
The human immunodeficiency virus is the causal agent of
AIDS. AIDS morbidity and mortality have led to efforts to
identify effective inhibitors of the replication of this virus.
Viral replication is driven by a molecular motor consisting
of the three viral enzymes: the reverse transcriptase, pro-
tease and integrase (IN). The genomic RNA of the virus is
used to produce a copy of viral DNA by reverse transcrip-
tion, and the last of these enzymes, integrase, catalyses the
covalent insertion of this DNA into the chromosomes of
the infected cells. Once integrated, the provirus persists in
the host cell and serves as a template for the transcription
of viral genes and replication of the viral genome, leading
to the production of new viruses. Integrase possesses two
major catalytic activities: an endonucleolytic cleavage at
each 3'-OH extremities of the viral genome, named 3'-
processing, and a strand transfer reaction leading to the
insertion of the processed viral DNA into the target DNA
by a trans-esterification mechanism. These catalytic func-
tions of the integrase are essential for the overall integra-
tion process and have thus been the object of intensive
pharmacological research. Since the end of the 1990s, sev-
eral inhibitors with genuine antiviral activity have been
identified and developed. Two of these compounds – MK-
0518 or raltegravir and GS9137 or elvitegravir – have
shown great promise and should ensure that integrase
inhibitors rapidly become an important class in the arse-
nal of antiretroviral drugs (ARVs) available [1]. In addi-
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efficiently catalyse other reactions: a third reaction,
named disintegration, corresponds to the apparent
inverse reaction of the strand transfer [2] although it is not
clear whether it may occur in the cell context. More
recently, a specific and internal cleavage catalysed by the
full-length IN has been observed in vitro [3]. This reaction
requires a symmetrical organisation of the DNA substrate
as well as a tetrameric organisation of the protein. From a
structural point of view, this reaction is related to the
endonucleolytic reaction of a restriction enzyme.
In vivo, the integrase oligomer and viral DNA molecule
form part of a preintegration complex (PIC), our knowl-
edge of which remains limited. The reverse transcriptase
(RT), matrix protein (MA), Vpr and the nucleocapsid pro-
tein (NC) are also present in this complex as well as cellu-
lar partners [4-7]. The presence of an intact integrase is
required for the stabilisation of preintegration complexes
and their transport into the nucleus: These non catalytic
functions of IN are also crucial for the viral replication
cycle. Indeed, a functional interaction between IN and RT
has been observed, suggesting that IN is involved, at least
indirectly, in controlling the synthesis of viral DNA [8-
10]. Furthermore, the interaction of particular IN struc-
tures with one or several cellular cofactors plays a key role
for the integration into host cell chromosomes. For
instance, LEDGF/p75 acts as a chromatin tethering factor
for IN [11,12]. All these observations pave the way for the
development of inhibitors targeting the interactions
between IN and either viral or cellular cofactors. These
alternative functions may constitute useful targets for the
future development of integrase inhibitors.
Integrase
Integrase is a 288-amino acid protein (32 kDa) encoded
by the end of the pol gene. It is produced as part of the
Gag-Pol polypeptide precursor, from which it is released
by viral protease-mediated cleavage. It has three inde-
pendent domains: (i) The N-terminal domain (amino
acids 1–49) that carries an HHCC motif analogous to a
zinc finger, and effectively binds Zn2+ [13], possibly
favouring protein multimerisation, a key process in inte-
gration [13,14]. (ii) The central domain or catalytic
domain (amino acids 50–212) encompassing a D, D-35,
E motif which is indispensable for the catalytic activity
and which is conserved between viral IN and trans-
posases. This central domain is also implicated in the
binding of the viral DNA extremities mainly via the
residus Q148, K156 and K159 [15-19]. All integrase activ-
ities strictly require the presence of a metallic cationic
cofactor which is coordinated by two residues of the cata-
lytic triad (D64 and D116 for HIV-1 IN) [20,21]. (iii) The
C-terminal domain (amino acids 213–288) binds non-
specifically to DNA and therefore is mainly involved in
the stability of the complex with DNA. No complete struc-
ture has yet been determined for the integrase protomer
(IN1–288), or for oligomers or complexes of these struc-
tures with DNA, due to poor solubility and interdomain
flexibility problems. However, several structures of iso-
lated domains or of two consecutive domains have been
reported [20-25].
Integrase functions in a multimeric form, as shown by
complementation experiments: mixtures of proteins, each
individually inactive, were found to be active [26-28]. For
example, an inactive catalytic triad mutant can be comple-
mented by an inactive integrase truncated at its C-terminal
end. Such a functional complementation can be observed
in virions [29]. In addition, the factors promoting inte-
grase multimerisation such as Zn2+ also stimulate the spe-
cific Mg2+-dependent activity of the enzyme [14],
indicating that functional enzyme is multimeric. Dimers
form at either end of the viral DNA molecule. These dim-
ers are responsible for 3'-processing activity [30-34]. Pairs
of dimers bring together the two ends of the viral DNA
and leads to the formation of a tetramer (dimer of dimer),
the active form for concerted integration [35,36]. During
its catalytic cycle, IN must bind simultaneously to the viral
substrate DNA and the target DNA. Current knowledge of
the organisation of this tetramer onto DNA is based exclu-
sively on models constructed from partial structural and
biochemical (cross-linking and site-directed mutagenesis)
data [24,37-40]. In a recent model, an IN tetramer is
bound to the two ends of the viral DNA, i.e. LTRs (Long
Terminal Repeat), and to a 26 base pairs host DNA mole-
cule in the presence of Mg2+ [40]. This model takes into
account the structural constraints deduced from the
model of the complex formed between DNA and a related
enzyme, the Tn5 transposase, and the observation that the
two ends of the viral DNA are integrated five base pairs
apart, corresponding to a distance of about 16 Å. This
model may provide a platform for the rational design of
new inhibitors. It is important to note that most of these
models support a symmetrical form of IN for concerted
integration. However, recently, Ren et al. have proposed
an asymmetric tetramer/DNA model for the concerted
integration suggesting that at least a reaction intermediate
could be asymmetric [39].
The catalytic activities of integrase (IN)
3'-processing and strand transfer
There is now substantial virological evidence that the pre-
cursor of integrated viral DNA, or provirus, is a linear viral
DNA generated by reverse transcription of the viral
genome. Two reactions are required for the covalent inte-
gration of viral DNA into the host DNA. The integrase
(IN) first binds to a short sequence at each end of the viral
DNA known as the long terminal repeat (LTR) and cataly-
ses an endonucleotide cleavage known as 3'-processing, inPage 2 of 13
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viral DNA (Fig 1). The resulting cleaved DNA is then used
as a substrate for integration or strand transfer leading to
the covalent insertion of the viral DNA into the genome of
the infected cell (Fig 1). This second reaction occurs
simultaneously at both ends of the viral DNA molecule,
with an offset of precisely five base pairs between the two
opposite points of insertion.
These two reactions also occur in vivo in a sequential man-
ner. The two reactions are also energetically independent.
In both cases, the reaction is a single-step trans-esterifica-
tion involving the disruption of a phosphodiester bond
by nucleophilic attack. In the first reaction, the bond con-
cerned is part of the viral DNA molecule and in the sec-
ond, the bond is in the target DNA. There is therefore no
covalent intermediate between the enzyme and the DNA
as it is observed during catalytic reaction of topoisomerase
or IN of lambda phage, for example. The removal of the
dinucleotides from the 5' overhang, of viral origin, and
DNA repair (i.e. polymerisation and ligation) are required
to complete the full integration reaction. One study sug-
gested that this might involve a DNA-dependent DNA
polymerase activity of the IN [41], but, to date, such a
polymerase activity of IN was not confirmed and it is gen-
erally thought that this DNA repair is performed by cellu-
lar mechanisms that can be reproduced in vitro with
purified host cell factors [42]. The final reaction thus
results in a viral DNA molecule, the provirus, integrated
into and collinear with the genomic DNA, with a charac-
teristic 5 base pairs duplication (in the case of HIV-1) of
genomic sequence flanking the integration site. Several
lines of evidence support a non-random integration with
preferential integration in transcription units for HIV-1
[43]. Integration is then mainly directed by interactions
between the pre-integration complex and chromatin.
From a DNA sequence point of view, it was recently
shown that integration occurs preferentially within sym-
metric sequences [44-46] (see # 2.3).
Both reactions (3'-processing and strand transfer) can be
reproduced in vitro using short double-stranded oligonu-
cleotides mimicking the sequence of the ends of the viral
LTR U5 or U3 in the presence of a recombinant integrase
[47]. 3'-processing is a highly specific reaction. This reac-
tion involves the removal of a dinucleotide, adjacent to
the highly conserved CA dinucleotide, from the 3' strand
of the U3 and U5 viral DNA LTRs. Mutations in this
sequence completely abolish activity, whereas the integ-
rity of flanking sequences is much less important [15,48].
The 3'-processing reaction corresponds to a nucleophilic
attack by a water molecule. However, other alternative
nucleophilic agents can be used such as glycerol but gen-
erally conduct to non-specific endonucleolytic cleavage
[49-51]. This mainly occurs when Mn2+ is used. The 3'-OH
of the unprocessed DNA can also be used directly as a
nucleophilic agent leading to 3'-5' cyclic dinucleotide
product [49]. The use of the physiological relevant cofac-
tor Mg2+ improves the specificity of the cleavage with
water as the mainly used nucleophilic agent.
During the same reaction, IN can catalyse, with a modest
yield, the strand transfer. In the strand transfer reaction,
the nucleophilic agent corresponds to the 3'-OH extremity
of the processed strand. It is possible to increase the yield
of the strand transfer with pre-processed oligonucleotides
[36]. By using an oligonucleotide mimicking one LTR
end, only a half-transfer reaction can be observed. In vitro,
long DNA fragments with two viral extremities can be
used to reproduce the concerted integration process which
corresponds to the simultaneous integration of two viral
ends [35,36,52,53]. Concerted integration appears less
tolerant to reaction conditions, i.e. enzyme preparation
and oligomerization state than strand transfer. Although
it was shown by different groups that IN alone is sufficient
to catalyse the concerted integration, viral or cellular pro-
tein, acting as cofactors for the integration process, such as
the viral nucleocapsid protein NC [54] and the cellular
proteins HMG I(Y) [55] and LEDGF [56-58] may increase
its efficacy. Interestingly, it was recently shown that, in
contrast to the half-transfer reaction, a higher reaction
yield was obtained for the concerted integration starting
from a blunt-ended as compared to a pre-processed DNA
substrate [36]. Furthermore, activity of IN is strongly
dependent on its oligomeric state [14,47,59]. In contrast
to 3'-processing which requires the dimeric form of IN
[31], it was shown that concerted integration requires a
tetrameric organization [32].
Both the 3'-processing and strand transfer reactions
require a metallic cofactor. This cofactor may be Mn2+ or
Mg2+, but Mg2+ is preferentially used in vivo. Indeed, there
is considerable experimental evidence to suggest that
Mg2+ is more physiologically relevant, particularly as the
specificity of the reaction is much greater in the presence
of this cation: (i) IN displays strong non-specific nuclease
activity in the presence of Mn2+ [60,61]. (ii) The tolerance
of sequence variation at the ends of the viral DNA mole-
cule is much greater in the presence of Mn2+ than in the
presence of Mg2+ [15,48]. (iii) Many IN mutations remain
silent in the presence of Mn2+ but not in the presence of
Mg2+. For example, mutations of the HHCC domain that
are deleterious to the virus in vivo affect 3'-processing and
integration activities in in vitro tests using Mg2+, but have
no such effect in tests using Mn2+ [62,63]. Furthermore,
zinc has no stimulatory effect on IN activity when using
Mn2+ as a cofactor while zinc stimulates the Mg2+-depend-
ent activity [14]. In the Pearson Hard-Soft Acid-Base the-
ory (HSBA), hards metal ions such as Mg2+ (with d0
electron configuration) are characterized by electronPage 3 of 13
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Catalytical activities of HIV-1 integraseFigure 1
Catalytical activities of HIV-1 integrase. The catalytical activities 3'-processing (A), strand-transfer reaction (B), disintegration 
(C) and palindrome cleavage (D) are represented. The domains of the protein responsible for these activities are depicted in 
the table above.
























































































Retrovirology 2008, 5:114 http://www.retrovirology.com/content/5/1/114clouds which are not easily deformed, in contrast to soft
metals ions such as Mn2+, with direct consequences on the
active site plasticity and reaction specificity for many
metal-dependent enzymes when comparing their activi-
ties under either Mg2+ or Mn2+ context. The presence of
Mg2+ generally leads to more stringent conditions for
catalysis in term of reaction specificity as found for RAG1/
2 proteins [64], Tn10 transposase [65], RNase H activity
[66]. HIV-1 integrase also displays such a differential
qualitative behaviour between Mg2+ and Mn2+-dependent
catalysis. It was also reported that IN/DNA complexes dis-
play different stabilities depending on the cofactor context
with IN/DNA complexes being more stable in the pres-
ence of Mn2+ than in the presence of Mg2+ [67-69]. Such a
differential stability of complexes is generally observed
using IN purified in the presence of detergent and
accounts for quantitative differences in term of enzymatic
activity when comparing Mg2+ and Mn2+. Indeed, IN from
detergent-containing preparations displays more Mn2+-
dependant than Mg2+-dependant activity as compared to
detergent-free preparations that quantitatively display
similar activities. The difference between cofactors has
pharmacological implications, as the apparent efficacy of
various IN inhibitors differs between tests using Mg2+ or
Mn2+ as a cofactor [70-72], and the effects of mutations
conferring drug resistance are often detectable only in
tests using Mg2+ as the cofactor [73]. These considerations
have led to the use of chemical groups chelating Mg2+ in
the rational design of integrase inhibitors. Such groups are
present in all the inhibitors developed to date, including
raltegravir and elvitegravir [1].
Whatever the activity tested, IN is characterized by an
overall slow cleavage efficiency. Furthermore, IN form sta-
ble complexes with both DNA substrate and DNA prod-
uct, limiting multiple turnover [74]. Taken together, these
features resemble to those observed for other polynucle-
otidyl-tranferases such as transposases. These enzymes
share a peculiar enzymatic property: they have evolved to
catalyse multi-sequential steps (two reactions for IN and
four for Tn5 transposase) in a single active site. A multi-
sequential reaction requires a strong binding of the
enzyme to the DNA product after each chemical step to
optimise the entire process but consequently diminishes
the overall enzymatic efficacy in term of turnover. How-
ever, this weak catalytic activity is not detrimental for
these enzymes in the cellular context, because a single
event of integration or transposition is sufficient for the
overall function. In vivo, this tight binding of IN to the
viral processed DNA most likely allows the complex to
remain associated after the 3'-processing reaction long
enough for subsequent integration. Two strategies have
been considered for the development of IN inhibitors:
screening using the unbound protein (before complex for-
mation) or screening with the preformed IN-viral DNA
complex. The success of these two approaches has been
demonstrated by the identification of (i) inhibitors of 3'-
processing targeting the DNA free enzyme and blocking
its binding to the viral DNA [75] and (ii) inhibitors of
strand transfer targeting the preformed complex more
related to the preintegration complex (PIC) [76]. These
two families of compounds are respectively called INBI
(IN DNA-Binding Inhibitors) and INSTI (IN Strand Trans-
fer Inhibitors) (Fig 2). Since the early 1990s, a number of
compounds inhibiting either 3'processing or strand trans-
fer have been identified in vitro [77,78]. The great stability
of the PIC and its presence in the cell throughout most of
the preintegration steps make this complex the most suit-
able target. Unfortunately, most of the INBI compounds
are inactive on the preformed complexes. Indeed only
strand transfer inhibitors or INSTIs have been shown to be
potent antiviral compounds. As they selectively target the
preformed IN-viral DNA complex and inhibit the binding
of the acceptor DNA (i.e. target DNA or host DNA), INSTI
compounds selectively inhibit the strand transfer reaction
and have no effect on the 3'-processing reaction [79]. One
such compound, Raltegravir (Isentress@), which was
developed based on early studies by Hazuda et al. [76],
was approved for clinical use in Autumn 2007 as the first
antiretroviral drug (ARV) targeting the viral integrase (IN).
This inhibitor act by binding to the IN-viral DNA com-
plex, close to the 3' end of the donor DNA, thereby selec-
tively blocking the strand transfer step; the IC50 values are
in the nanomolar range both in vitro and ex vivo with a
high therapeutic index [80]. Unfortunately, variants of the
virus resistant to this inhibitor have already been reported
[80]. The emergence of resistant virus in vivo should
prompt both a search for new INSTIs and reassessment of
the potential inhibitory activity of INBIs (such as styryl-
quinolines or SQL) which have been shown to be inhibi-
tors of 3'processing in vitro with significant inhibitory
activity against viral replication in cell cultures (Fig 2)
[81].
The presence either of the catechol or an another group on
the SQLs able to form a complex of coordination with a
divalent ion suggests that these compounds interact with
the active site of the enzyme by a chelation with the metal-
lic cofactor. These compounds are mainly inhibitors of
the 3'-processing reaction, and their mechanism of action
in vitro can be assimilated to a competitive mechanism.
Recently, experiments based on fluorescence anisotropy
demonstrated that SQLs are DNA-binding inhibitors of
HIV-1 IN [75]. In summary, INBI compounds primarily
compete with the binding of the donor DNA (viral DNA)
while INSTI compounds compete with the binding of the
acceptor DNA (target DNA). However, the mechanism of
inhibition of SQLs in the cell context is not completely
understood. These compounds appear to act at steps prior
to integration, more particularly during RT [82] andPage 5 of 13
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evidenced by the appearance of resistance mutation in IN
sequence. It is then suggested that, ex vivo, non catalytic
region of IN are targeted by SQs (see paragraph "non cat-
alytic role of IN"). It is interesting to note that the two
classes of IN inhibitors, INBI and INSTI, induce distinct
resistant mutations [76,82,84-86].
Disintegration
A third reaction, disintegration, is observed in vitro (Fig 1).
Disintegration may be considered to be the reverse of the
strand transfer reaction [2]. Unlike the 3'-processing and
strand transfer reactions which requires the full-length
protein, the disintegration reaction can be catalysed by the
catalytic domain alone (IN55–212) or by truncated pro-
teins, IN1–212 or IN55–288 [47,87,88]. This activity was
widely used for testing the competitive mechanisms of
certain inhibitors. There is currently no experimental evi-
dence to suggest that this reaction occurs in vivo.
A new internal specific activity
Recently, our group has identified a new internal and spe-
cific cleavage activity in vitro of HIV-1 IN [3]. Until now,
all attempts to study a specific internal endonucleolytic
cleavage in vitro have failed. Vink et al. have demonstrated
that when the CA dinucleotide, indispensable for the 3'-
processing, was separated by more than 2 nucleotides
from the 3'-OH end, the activity was dramatically
impaired [89]. Nevertheless, we have demonstrated that
oligonucleotides mimicking the palindromic sequence
found at the LTR-LTR junction of the 2-LTR circles (found
in infected cells) were efficiently cleaved at internal posi-
tions by HIV-1 IN, with cleavage kinetics comparable to
the 3'-processing reaction (Fig 1). This reaction occurs
symmetrically on both strands, with a strong cleavage at
the CA dinucleotide (corresponding to the CA sequence
used for the 3'-processing reaction). A second weaker
cleavage site appears after the next adenine (TA sequence)
in the 5'-3' direction. Furthermore, HIV-1 IN can effi-
ciently cleave a plasmid mimicking the 2-LTR circles spe-
cifically at the LTR-LTR junction. The specificity of this
reaction is similar to the one catalysed by transposases
which cleave the DNA substrate after a CA or TA dinucle-
otide [90]. Such internal cleavages are not observed using
a mutant of the catalytic site (E152A) testifying that the
DDE triad is also implicated in this reaction. In addition,
this novel activity is stringent and highly specific as (i) it
occurs with the physiological metallic cofactor (Mg2+) and
not only Mn2+, (ii) only the full-length IN is competent
for the internal cleavage of the palindrome, in contrast to
the disintegration reaction that is efficiently catalysed by
truncated proteins such as IN55–212, IN55–288, IN1–212 and
(iii) it does not sustain any mutation in the sequence of
the LTR-LTR junction. Furthermore, the cleavage of the
LTR-LTR junction requires the tetrameric forms of IN
whereas the 3'-processing reaction is efficiently catalysed
by a dimer [31,32]. This new activity seems to be general-
ised to other retroviral IN as reported earlier for PFV-1 IN
Some anti-integrase compoundsFigure 2
Some anti-integrase compounds. Styrylquinoline, a member of the INBI (IN DNA-Binding Inhibitors) compound and beta dice-
tonic acid, Raltegravir and Elvitegravir, members of the INSTI (IN Strand Transfer Inhibitors) compounds, are represented.
Styrylquinoline Beta-dicetonic acid Raltegravir (MK-0518)
Elvitegravir (JTK-303)Page 6 of 13
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age activity, it is important to note that both IN are strictly
restricted to their own cognate palindromic sequence:
HIV-1 IN is unable to cleave the PFV LTR-LTR junction
and PFV-1 IN is unable to cleave the HIV-1 LTR-LTR junc-
tion.
Recently, mapping of extensive integration sites, notably
for HIV-1, put in light the existence of a weak palindromic
consensus [44-46]. It is important to note that the
sequence of the weak palindromic consensus is similar,
although not identical, to the one found at the LTR-LTR
junction. This specific endonucleolytic activity on a palin-
dromic LTR-LTR junction as well as the symmetrical
organization of integration sites reveal a common struc-
tural feature of IN: IN intrinsically prefers to bind to sym-
metric DNA sequences. Moreover, we have found that
tetramers catalyses the cleavage of the palindromic
sequence while others have suggested that the same oligo-
meric form is responsible for the concerted integration in
the context of the synaptic complex [35,36]. Therefore,
one could reasonably imagine that the same multimeric
organization of IN (i.e. the tetrameric form) is stabilised
by a corresponding symmetry at the DNA level, either at
the viral DNA (LTR-LTR junction) or at the target level
(integration sites).
In vivo, unintegrated viral DNA could represent 99% of
total viral DNA in infected cells [93] underlying that inte-
gration is a rare event. Un-integrated DNA is mainly linear
but also circular – 1-LTR or 2-LTR circles. In the absence of
integration (for example using strand-transfer inhibitors
such as diketo acids), at least the 2-LTR circular forms of
viral DNA, which are usually believed to be dead-end
molecules, are accumulated [94]. It is tempting to specu-
late about a possible role of 2-LTR circles in a subsequent
integration process after removing the drug pressure,
mediated by the ability of IN to cleave the LTR-LTR junc-
tion. However, to date, although IN is able to cleave the
LTR-LTR junction in vitro, there is no proof that such a
cleavage can occur in vivo and thus that 2-LTR circles could
be an efficient precursor for integration.
Modulation of IN activity
Several cellular and viral proteins have been reported to
stimulate IN activities in vitro as well as in vivo. Among
these cofactors, some proteins are known to interact
directly with IN and thus enhance its solubility or favours
an active conformation of IN, while other proteins do not
physically interact with IN but could indirectly stimulate
IN activities as found for proteins playing a structural role
on DNA conformation.
For instance, in the group of IN interactors, the yeast chap-
eroning protein, yHSP60, was described by Parissi and
colleagues to interact directly with HIV-1 IN [95]. It has
also been demonstrated that the human counterpart of
the yHSP60, hHSP60, was able to stimulate the in vitro
processing as well as joining activities of IN, suggesting
that hHSP60-IN interaction could allow IN to adopt a
more competent conformation for activity or prevent IN
from aggregation [95]. However, further investigations
must be done to confirm the potential role of HSP60 in
the viral life cycle.
LEDGF/p75, Lens Epithelial Derived Growth Factor, has
been reported to interact with IN and stimulate both con-
certed integration and strand transfer. Addition of recom-
binant LEDGF/p75 to an in vitro mini HIV-based IN assay
enhanced the strand transfer activity of the recombinant
HIV-1 IN [56]. This stimulation is highly dependent of the
ratio between IN and LEDGF used for the reaction [58].
Probably, LEDGF/p75 has a double effect on IN. The first
one is similar to the one described for HSP60. Indeed, it
was shown that LEDGF-IN complex displays a more
favourable solubility profiles as compared to the free IN
[96]. In the same publication, a second effect could
explain the enhancement of IN activity as LEDGF/p75
binding to DNA concomitantly increases IN-DNA affinity
[96]. Concerning more specifically the concerted integra-
tion, it has been reported that LEDGF increases the stabi-
lisation of the tetrameric state of IN which is responsible
for the concerted integration [97]. In vivo, LEDGF dis-
plays an important role in the targeting of the viral inte-
gration [98] (see also # 2.5).
It is important to note that IN activity is also highly regu-
lated by the structure of the viral and host DNA substrates
which can be influenced by protein interactions on DNA.
Pruss et al. studied the propensity of IN to integrate an oli-
gonucleotide mimicking the HIV LTR into either DNA
molecules of known structure or nucleosomal complexes
[99,100]. Results highlight that the structure of the target
greatly influences the site of integration, and that DNA
curvature, flexibility/rigidity in solution, all parameters
influence the frequency of integration. Furthermore, using
a model target comprising a 13-nucleosome extended
array that includes binding sites for specific transcription
factors and which can be compacted into a higher-ordered
structure, Taganov et al. demonstrated that the efficiency
of the in vitro integration was decreased after compaction
of this target with histone H1 [101]. Consequently, both
intrinsic DNA structure and the folding of DNA into chro-
mosomal structures will exert a major influence on both
catalysis efficiency and target site selection for the viral
genome integration. The structure of the viral DNA also
greatly influences IN activity [102], as illustrated by alter-
ations in the minor groove of the viral DNA which result
in a greater decrease in 3'-processing activity than majorPage 7 of 13
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structure of the viral DNA for IN activities.
Several cellular proteins greatly influence the structure of
the viral DNA and thus modulate IN activities. For exam-
ple, BAF (Barrier-to-autointegration factor), a component
of the functional HIV-1 pre-integration complex, stimu-
lates the integration reaction in the PIC complex
[103,104]. The effect of BAF on integration is probably
due, in vitro, to its DNA binding activity and its effect on
the viral DNA structure [105]. HMG I(Y), a protein part-
ner of the HIV-1 PICs, has been also described to stimu-
late concerted integration in vitro. Li and colleagues
demonstrated that HMG I(Y) can condense model HIV-1
cDNA in vitro, possibly by approximating both LTR ends
and facilitating IN binding by unwinding the LTR termini
[106]. These data suggest that binding of HMG I(Y) to
multiple cDNA sites compacts retroviral cDNA, thereby
promoting formation of active integrase-cDNA complexes
[106]. In addition, Carteau and colleagues led to the find-
ing that concerted integration can be stimulated more
than 1,000-fold in the presence of the nucleocapsid pro-
tein in comparison to integrase alone under some condi-
tions of reaction [54]. To date, the effect of the NC on
concerted integration is not clear but is probably due its
capability to promote DNA distorsion.
Another IN cofactor, INI-1 (Integrase Interactor 1), has
been described to enhance IN activity probably by struc-
tural and topological effect on DNA. INI-1, is one of the
core subunits of the ATP-dependent chromatin remodel-
ling complex SWI/SNF that regulates expression of
numerous eukaryotic genes by altering DNA/histone
interaction. INI-1 was identified by a two-hybrid system
that binds to IN and enhances the strand transfer activity
of the protein [107]. Taking into account that INI-1 inter-
acts with IN, it is not excluded that a solubility effect
induced by protein-protein interaction may account for
the stimulation effect on IN activity as reported for
LEDGF/p75. It is important to note that conflicting results
concerning the role of INI-1 in the HIV-1 life cycle have
been reported. It has been described that SNF5/INI-1
interferes with early steps of HIV-1 replication [108].
Boese and colleagues found no effects on viral integration
in cells depleted for INI-1 [109], whereas it has been pro-
posed that INI-1 was required for efficient activation of
Tat-mediated transcription [110]. The comprehension of
the role of such IN partners, as well as the discovery of
novel partners will be crucial to reproduce more authentic
integrase complexes for mechanistic studies and develop-
ment of IN inhibitors.
Targeting viral integration
Additionally, interactions between IN and cellular protein
partners play key role in the targeting of integration. A sys-
tematic study of the sites of HIV DNA integration into the
host DNA has shown that integration is not entirely ran-
dom. Analysis of integration sites in vivo indicates that
HIV tends to integrate into sites of active transcription
[43]. It is likely that this integration bias results from inter-
actions between PICs and components of cellular origin
in relationship with the chromatin tethering. Several cel-
lular cofactors, including INI-1 [107,111], BAF [103,112],
Ku [113] and LEDGF/p75 [114], are known to interact
with the PIC in the nucleus. Among these proteins, at least
INI-1 and LEDGF/p75 physically interact with IN
[107,115]. Recent work with LEDGF/p75 strongly sug-
gests that this cofactor is actually responsible for targeting
integration [11]. LEDGF/p75 silencing modifies the bias
from transcription units to CpG islands [43,116]. As
LEDGF/p75 is essential for HIV-1 replication and LEDGF/
p75 interacts directly with IN, the domain of interaction
between these two proteins is therefore a promising target
for the development of integrase ligands with antiviral
activity. Although no direct interaction between IN and
BAF or Ku was described, it is suggested that these two
cofactors could influence the profile or efficiency of inte-
gration [117,118]. For example, interaction of BAF with
emerin, an internal-inner-nuclear-envelope protein,
could favour the access of the PIC to the chromatin and
thus facilitate integration [119]. In relationship with chro-
matin, it was recently described that the C-terminal
domain of IN is acetylated by a histone acetyl transferase
(HAT) [120]. However, the effect of IN acetylation on
integration in vivo remains unclear [121].
Non catalytic activities of IN
IN plays a key role for retroviral replication because of its
catalytical activities. In addition, IN has also non catalytic
properties that are essential for the replication cycle.
Mutations of IN can be divided into two groups. The first
class of mutations (Class I) includes mutants that are
affected in their catalytic activities. For instance, one
mutation in either the three amino acids of the DDE triad
abolishes the catalytic activities of IN. The second class of
mutations (Class II mutants) disturbs other steps of the
retroviral replication and corresponding purified inte-
grase mutants display wild-type level of activity.
Several mutations of IN displayed an in vivo DNA synthe-
sis defect and a block of viral replication at the reverse
transcription level [8,9,122-124]. A structural general
defect at the level of the retrotranscription complex which
includes RT and IN may account for such a phenotype.
Indeed, several studies suggest a physical interaction
between IN and RT [9]. Such a defect in DNA synthesis
can be also observed when using SQL compounds which
target integrase, as evidenced by resistance mutations
study, but primarily affect the reverse transcription step
[82].Page 8 of 13
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translocation in the nucleus. In fact, in non-dividing
infected cells, such as macrophages, the PIC must cross
the nuclear membrane to reach the chromosomal DNA.
This involves an active mechanism, the determinants of
which remain unclear [125,126]. It has been reported by
De Soultrait et al. that L2, which corresponds to the C-end
half of the yeast STU2p, a microtubule-associated protein
(MAP), interacts with IN. STU2p is an essential compo-
nent of the yeast spindle pole body (SPB), which is able to
bind microtubules in vitro. This interaction was observed
in vitro and also in vivo in a yeast model [127]. The identi-
fication of components of the microtubule network asso-
ciated with IN suggests a role of this complex in the
transport of HIV-1 PIC to the nucleus and supports recent
particle tracking data suggesting that PIC is characterized
by a microtubule-directed movement [128].
Integrase and at least two other components of the PIC,
Vpr and MA, have karyophilic properties [129] suggesting
that several distinct mechanisms could be involved in the
nuclear import. The integrase enzyme includes several
sequence motifs likely to act as nuclear localisation signals
(NLSs), including at least one known to interact with the
nuclear import receptor, this motif being located in the C-
terminal domain [126]. A sequence within the catalytic
core including the V165 and R166 residues may also con-
tribute to the karyophilic properties of integrase [130],
although this remains a matter of debate [124,131]. In
any case, the mutation of these various sequences does
not completely abolish the nuclear translocation of PICs,
confirming that there are complementary and/or redun-
dant translocation mechanisms. Recently, a novel partner
of IN in the nuclear translocation has been described by
Christ and colleagues [132]. Using yeast two-hybrid and
pull-down experiments, the transportin-SR2 (TRN-SR2)
was shown to interact with IN. By RNAi experiment on
infected cells, SR2 was clearly validated as an essential
partner in the translocation of IN and consequently of the
PIC into the nucleus of infected cells.
Finally, integrase could be indirectly involved in the regu-
lation of transcription of integrated provirus. After the
integration process, IN could be tightly bound to the inte-
grated DNA and then, the degradation of IN by the protea-
some-ubiquitin pathway was proposed to regulate the
transcription of viral genes. Indeed, Dargemont and col-
laborators have found that integrase interacts with VBP1
(von Hippel-Lindau binding protein 1), a binding partner
of Cul2/VHL ligase complex involved in the polyubiquit-
ylation process [133].
Conclusion
In conclusion, remarkable progress has been made
towards understanding the structure of the pre-integration
complex formed by HIV integrase and viral DNA. This
new knowledge has led to considerable improvements in
the methods used to search for compounds active against
this enzyme. Several families of inhibitors have now been
identified, including at least one – strand transfer inhibi-
tors – currently in the advanced stages of clinical develop-
ment and giving results sufficiently promising for one
molecule (Raltegravir) to have obtained a licence in Octo-
ber 2007 for release in the United States. The identifica-
tion of several new integrase cofactors will provide us with
a clearer picture of the determinants of integration in vivo,
opening up new possibilities for pharmacological
research [134]. There is no doubt that interest in the struc-
tural biology of integrase will be substantially stimulated
by the release of the first integrase inhibitors onto the
market and, unfortunately, by the likely emergence of
resistant viruses.
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